These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38343109)

  • 1. Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non-gemfibrozil fibrate trials.
    Doi T; Langsted A; Nordestgaard BG
    J Intern Med; 2024 May; 295(5):707-710. PubMed ID: 38343109
    [No Abstract]   [Full Text] [Related]  

  • 2. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
    N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
    Nerbrand C; Nyberg P; Nordström L; Samsioe G
    Maturitas; 2002 May; 42(1):55-62. PubMed ID: 12020980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients.
    Chen MF; Wang TD; Yeh HT; Hsu HC; Lee YT
    Eur J Clin Invest; 2001 Aug; 31(8):707-13. PubMed ID: 11473572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
    Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
    Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
    Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.
    Doggrell SA
    Expert Opin Pharmacother; 2001 Jul; 2(7):1187-9. PubMed ID: 11583069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
    Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
    Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
    Zimetbaum P; Frishman WH; Kahn S
    J Clin Pharmacol; 1991 Jan; 31(1):25-37. PubMed ID: 2045526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study].
    Scheen AJ
    Rev Med Liege; 1999 Sep; 54(9):773-5. PubMed ID: 10589275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical results with gemfibrozil.
    Pickering JE
    Am J Cardiol; 1983 Aug; 52(4):39B-40B. PubMed ID: 6351579
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
    McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
    Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients.
    Hanes DS; Nicholson PG; Raval DD; Hooper FL; Behrens MT; Weir MR
    Am J Ther; 1997; 4(2-3):85-91. PubMed ID: 10423597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
    Bell DS
    Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
    Kayıkçıoğlu M; Shahbazova S; İbrahimov F; Can LH
    Turk Kardiyol Dern Ars; 2020 Jun; 48(4):359-367. PubMed ID: 32519982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of fibrate drugs in coronary heart disease patients with normal cholesterol levels.
    Havel RJ
    Circulation; 1997 Oct; 96(7):2113-4. PubMed ID: 9337175
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.